Phase 2 study of EGEN-001 for the treatment of ovarian cancer

EGEN, Inc. announced that the first Phase 2 clinical trial using EGEN-001 for the treatment of recurrent ovarian cancer is now open for enrollment. The product utilizes EGEN's proprietary TheraPlas delivery technology and is composed of interleukin-12 (IL-12) gene formulated with a biocompatible delivery polymer.

IL-12 is a potent cytokine which works by enhancing the body's immune system against cancer and inhibiting tumor blood supply.

For more information call (256) 512-0077 or visit www.egeninc.com.